If approved, the targeted IGF-1 fusion protein would become the only treatment available for late-window stroke patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback